Welcome to our dedicated page for Arbutus Biopharm SEC filings (Ticker: ABUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arbutus Biopharma Corporation (Nasdaq: ABUS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arbutus is a clinical-stage biopharmaceutical company focused on infectious disease, particularly chronic hepatitis B virus (cHBV) infection, and its filings offer detailed insight into its operations, risks and strategic priorities.
Through current reports on Form 8-K, Arbutus discloses material events such as quarterly financial results, corporate updates, changes in directors and executive officers, and significant agreements. Recent 8-K filings referenced by the company include announcements of financial results for multiple quarters, the termination of a license agreement with Qilu Pharmaceutical resulting in the reacquisition of imdusiran rights in Greater China and Taiwan, and updates on patent litigation against Moderna and Pfizer/BioNTech related to lipid nanoparticle (LNP) technology used in COVID-19 vaccines.
Filings also document key legal milestones, including claim construction rulings in litigation against Pfizer/BioNTech and scheduling orders for jury trials in U.S. litigation against Moderna, as well as the initiation of international enforcement actions across numerous countries. These documents help investors understand how Arbutus and its licensee Genevant Sciences are seeking to protect and enforce LNP intellectual property.
On this page, users can review Arbutus’ 8-Ks and, via the SEC, its annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain information on research and development expenses, restructuring charges, cash, cash equivalents and marketable securities, and other financial metrics. Stock Titan’s AI-powered tools can assist by summarizing lengthy filings, highlighting key sections related to cHBV clinical programs, LNP litigation, and corporate restructuring, and helping readers quickly identify items such as risk factor updates and material agreements.
For those researching ABUS stock, Arbutus’ hepatitis B pipeline, or the status of its LNP-related lawsuits, this SEC filings page serves as a structured entry point into the company’s official regulatory record, with real-time updates as new documents are posted to EDGAR.
Arbutus Biopharma (NASDAQ:ABUS) announced the termination of its technology transfer and license agreement with Qilu Pharmaceutical Co., Ltd. The agreement, originally established in December 2021, granted Qilu exclusive rights to develop, manufacture, and commercialize imdusiran in Greater China and Taiwan.
The mutual termination, effective June 20, 2025, involves no financial payments and results in all rights for imdusiran in Greater China and Taiwan reverting to Arbutus. This decision aligns with Qilu's pipeline reprioritization and Arbutus's strategic focus on efficient pipeline advancement.